Tirzepatide (Mounjaro / Zepbound)
dual GIP + GLP-1, strongest results
Tirzepatide is one of the most effective compounded GLP-1/GIP weight loss medications available — activating both GLP-1 and GIP receptors for stronger results. Many patients experience significant weight loss with provider-supervised treatment at all 3 Silicon Valley locations.
- Dual GIP + GLP-1 mechanism
- Provider-supervised program
- 20–22% avg body weight loss
- Monthly monitoring & support
- Free consultation
Schedule Your Tirzepatide Appointment
Choose any of our 3 Silicon Valley locations. Walk-ins also welcome — no appointment required for consultation. 📍 Weight Loss at Sunnyvale Clinic
How Tirzepatide produces superior weight loss
💊 Tirzepatide is the active ingredient in Mounjaro (diabetes) and Zepbound (obesity). Unlike Semaglutide which targets GLP-1 receptors alone, Tirzepatide activates both GLP-1 and GIP receptors — a dual mechanism that produces greater appetite suppression and significantly higher average weight loss in clinical trials.clinical trials.
- Activates both GIP and GLP-1 receptors simultaneously
- GIP activation enhances appetite suppression beyond GLP-1 alone
- Slows gastric emptying — you stay full longer after meals
- Reduces food cravings and overall calorie intake
- Promotes fat utilization for energy (not just calorie restriction)
- Significantly improves insulin sensitivity and blood sugar
- Average 20.9% body weight loss at 15mg dose (72 weeks)
- Up to 52 lbs lost in participants with obesity
- Outperformed Semaglutide in head-to-head (SURMOUNT-5) trial
- Major reduction in HbA1c in patients with diabetes
- Improved cardiovascular risk markers
- Sustained results with continued use
Your provider-supervised Tirzepatide program
We use a slow-titration protocol to help your body adjust gradually — minimizing side effects while building toward your optimal therapeutic dose.
Comparing the two leading weight loss medications
Both medications are excellent — the right choice depends on your goals, health history, and insurance coverage.
Tirzepatide weight loss — frequently asked questions
Book online using any of the 3 clinic buttons above, or walk in during clinic hours. At your first visit, our licensed provider reviews your health history and confirms Tirzepatide is appropriate for you.
Clinical trials (SURMOUNT) show Tirzepatide produces greater average weight loss — approximately 20–22% vs 15% with Semaglutide. However, the best medication depends on your individual health history, insurance coverage, and how your body responds. Our providers help you decide.
Coverage varies. Mounjaro may be covered for Type 2 diabetes. Zepbound coverage for obesity is growing but varies by plan. Our team will help check your insurance benefits at your consultation. Self-pay options are available.
Clinical trials (SURMOUNT) show Tirzepatide produces greater average weight loss — approximately 20–22% vs 15% with Semaglutide. However, the best medication depends on your individual health history, insurance coverage, and how your body responds. Our providers help you decide.
Common side effects include nausea, diarrhea, vomiting, and constipation — especially in the early weeks. Like Semaglutide, we start at a low dose (2.5mg/week) and titrate gradually to minimize side effects. Most patients adjust well within the first few weeks.
Tirzepatide is a once-weekly subcutaneous injection, starting at 2.5mg and titrated up to a maximum of 15mg. Our provider teaches self-injection at your first appointment — the pen device is simple and the needle is very small.
Both contain the same active ingredient — tirzepatide. Mounjaro is indicated for Type 2 diabetes. Zepbound is indicated specifically for obesity and weight management. The main difference is the FDA approval label — your provider will prescribe the appropriate one based on your diagnosis.
Semaglutide activates only GLP-1 receptors. Tirzepatide activates both GLP-1 and GIP receptors — a dual mechanism. GIP activation appears to enhance appetite suppression beyond GLP-1 alone, which explains the greater average weight loss seen in trials.
Tirzepatide weight loss — 3 Silicon Valley clinics
Start your Tirzepatide program —
free consultation today.
Provider-supervised Tirzepatide (Mounjaro/Zepbound) at all 3 Silicon Valley locations. Average 20–22% weight loss.
Call during clinic hours